Exit / M&A
Peplin - LEO Pharma to Acquire Peplin for US$287.5m
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Chairman and CEO, Peplin Inc
Tom Wiggans
Roles
| Role | Organisation | Sources |
|---|---|---|
| Chairman and CEO | Peplin Inc | GBS Ventures (Thu 3 Sep 2009), GBS Ventures (Thu 23 Jul 2009), GBS Ventures (Tue 19 May 2009), GBS Ventures (Thu 8 Jan 2009), GBS Ventures (Tue 16 Dec 2008), GBS Ventures (Mon 18 Aug 2008), GBS Ventures (Mon 18 Aug 2008) |
| Chairman of the Board and Chief Executive Officer (former) | Connetics Corporation | GBS Ventures |
| President and Chief Operating Officer (former) | CytoTherapeutics | GBS Ventures |
Coverage
Stories naming Tom Wiggans. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
News
Peplin Initiates its Final Phase 3 Clinical Trial for PEP005 Gel in AK
Peplin has begun a second Phase 3 trial of its skin-lesion gel, seeking to confirm earlier clearance results at non-head sites, with a regulatory filing planned for mid-2010.
News
Peplin `positive' on trial of sun spot treatment
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
News
Positive Results for Peplin's Phase IIb AK Trial
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.
News
Peplin Completes Enrolment for its First Phase III AK Clinical Trial
ASX-listed biotech Peplin has finished enrolling 250 patients in the first Phase III trial of its PEP005 Gel treatment for actinic keratosis, with results expected in H1 2009.
Unnamed stage
US$24m
Peplin Announces Executive Management Appointments
Peplin hires Tom Wiggans as CEO and Eugene Bauer as President/CMO while Michael Aldridge steps down; the dermatology company also announces a US$24m capital raising and a merger agreement with Neosil.
Also GBS Ventures